Taking into account that glutaminase inhibition monotherapy is known to be insufficient and that GLS inhibitors are increasingly used in combination with other cancer therapies [68], our results suggest that a combination of GLS and G6PD inhibitors could be a promising strategy to target glutamine addiction in colon cancer and to disrupt ROS balance efficiently. This evidence concerns the gene GLS and malignant colon neoplasm.